Adial Pharmaceuticals (ADIL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ADIL · Stock Price

USD 1.42-14.08 (-90.84%)

Market Cap: $2.1M

Historical price data

Market Cap: $2.1MPipeline: 1 drug (1 Phase 3)Founded: 2010HQ: Glen Allen, United States

Sector Ranking#374 in Small Molecule Drugs #153 in Diagnostics & Precision Medicine

Overview

Adial Pharmaceuticals is focused on developing genetically targeted therapies for addiction, with an initial emphasis on Alcohol Use Disorder (AUD). The company's core achievement is advancing its lead candidate, AD04, into Phase 3 trials, supported by a proprietary companion diagnostic to identify optimal patient responders. Its strategy hinges on leveraging precision medicine to improve treatment efficacy and secure a differentiated position in the addiction therapeutics market, while navigating regulatory pathways and exploring strategic partnerships for commercialization.

Alcohol Use DisorderAddiction

Technology Platform

A genetically targeted pharmacotherapy platform integrating a serotonin-3 receptor antagonist therapeutic with a proprietary companion diagnostic genetic test to identify patient subpopulations most likely to respond to treatment for addiction disorders.

Pipeline

1

1 drug in pipeline1 in Phase 3

Drug	Indication	Stage	Watch
AD04 (ondansetron) + Matching placebo	Alcohol Use Disorder	Phase 3

Opportunities

The primary opportunity is addressing the vast, underserved multi-billion dollar market for Alcohol Use Disorder (AUD) with a first-in-class, genetically targeted therapy.

Evolving FDA policies that may reduce the pivotal trial burden and growing legislative support for new AUD treatments provide favorable tailwinds.

Strategic partnerships, like the European framework with Molteni, offer pathways to non-dilutive funding and global commercialization.

Risk Factors

The company faces extreme clinical and regulatory risk, as the lead program's success depends on validating a genetic hypothesis in a pivotal trial and securing FDA approval.

Severe financial risk exists due to a pre-revenue status, reliance on equity financing, and a history of net losses, creating potential for dilution or insolvency.

Additional risks include market acceptance of a precision medicine approach, payer reimbursement, and competition.

Competitive Landscape

Adial competes in the AUD space against established generic pharmacotherapies (naltrexone, acamprosate) and a growing pipeline of novel mechanisms from other biotechs. Its competitive differentiation is its genetically targeted, precision medicine strategy, which creates a potential niche. However, it must prove this approach offers superior efficacy to gain market share against both existing standards of care and future innovative entrants.